lactic acid has been researched along with Dementia Praecox in 31 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydrochloric thiothixene (HT) is an antipsychotic drug used in the treatment of various psychoses including schizophrenia, mania, polar disorder, and in behavior disturbances." | 7.80 | Injectable long-term control-released in situ gels of hydrochloric thiothixene for the treatment of schizophrenia: preparation, in vitro and in vivo evaluation. ( Hongzhuo, L; Lihong, W; Qiuyuan, L; Xin, C, 2014) |
| "The response to treatment with imipramine or clonazepam was evaluated in patients with panic disorder." | 7.68 | [Treatment of patients with panic disorder and an elevated urinary excretion of MHPG using imipramine or clonazepam]. ( Carreira, I; Casique, M; Lima, L; Morales, M; Silva, C, 1992) |
| "Aripiprazole was encapsulated in biocompatible polycaprolactone microsphere by o/w emulsion solvent-evaporation method in order to achieve sustained release of the drug for several weeks after single subcutaneous administration." | 5.62 | Long Acting Polycaprolactone Based Parenteral Formulation of Aripiprazole Targeting Behavioural and Biochemical Deficit in Schizophrenia. ( Kaur, L; Sinha, VR, 2021) |
| "Risperidone release was assessed in vitro and in vivo in rats, and Level A, B and C correlations (IVIVCs) attempted for all." | 5.36 | In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. ( Amann, LC; Gandal, MJ; Liang, Y; Lin, R; Siegel, SJ, 2010) |
| "Hydrochloric thiothixene (HT) is an antipsychotic drug used in the treatment of various psychoses including schizophrenia, mania, polar disorder, and in behavior disturbances." | 3.80 | Injectable long-term control-released in situ gels of hydrochloric thiothixene for the treatment of schizophrenia: preparation, in vitro and in vivo evaluation. ( Hongzhuo, L; Lihong, W; Qiuyuan, L; Xin, C, 2014) |
| "The preparation and investigation of sustained-release risperidone-encapsulated microspheres using erodible poly(D, L-lactide-co-glycolide) (PLGA) of lower molecular weight were performed and compared to that of commercial Risperdal Consta™ for the treatment of schizophrenia." | 3.77 | Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation. ( Li, X; Li, YX; Meng, QF; Shi, YN; Su, ZX; Teng, LR; Teng, LS; Wang, LX, 2011) |
| "The response to treatment with imipramine or clonazepam was evaluated in patients with panic disorder." | 3.68 | [Treatment of patients with panic disorder and an elevated urinary excretion of MHPG using imipramine or clonazepam]. ( Carreira, I; Casique, M; Lima, L; Morales, M; Silva, C, 1992) |
| "Aripiprazole was encapsulated in biocompatible polycaprolactone microsphere by o/w emulsion solvent-evaporation method in order to achieve sustained release of the drug for several weeks after single subcutaneous administration." | 1.62 | Long Acting Polycaprolactone Based Parenteral Formulation of Aripiprazole Targeting Behavioural and Biochemical Deficit in Schizophrenia. ( Kaur, L; Sinha, VR, 2021) |
| "Glycylglycine was also significantly (p=0." | 1.46 | Metabolic profile alterations in the postmortem brains of patients with schizophrenia using capillary electrophoresis-mass spectrometry. ( Fujii, T; Hattori, K; Kunugi, H; Miyakawa, T; Ohashi, Y; Sato, H, 2017) |
| "Risperidone release was assessed in vitro and in vivo in rats, and Level A, B and C correlations (IVIVCs) attempted for all." | 1.36 | In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. ( Amann, LC; Gandal, MJ; Liang, Y; Lin, R; Siegel, SJ, 2010) |
| " The results have confirmed that the D-optimal experimental design technique can be successfully employed for designing the long acting microsphere dosage form." | 1.35 | D-optimal designing and optimization of long acting microsphere-based injectable formulation of aripiprazole. ( Nahata, T; Saini, TR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (9.68) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 5 (16.13) | 29.6817 |
| 2010's | 18 (58.06) | 24.3611 |
| 2020's | 4 (12.90) | 2.80 |
| Authors | Studies |
|---|---|
| Utomo, E | 1 |
| Domínguez-Robles, J | 1 |
| Moreno-Castellanos, N | 1 |
| Stewart, SA | 1 |
| Picco, CJ | 1 |
| Anjani, QK | 1 |
| Simón, JA | 1 |
| Peñuelas, I | 1 |
| Donnelly, RF | 1 |
| Larrañeta, E | 1 |
| Xie, J | 1 |
| Hong, S | 1 |
| Zhang, X | 1 |
| Li, Y | 3 |
| Xie, R | 1 |
| Kaur, L | 1 |
| Sinha, VR | 1 |
| Sun, L | 1 |
| Min, L | 1 |
| Li, M | 1 |
| Shao, F | 1 |
| Dogan, AE | 1 |
| Yuksel, C | 1 |
| Du, F | 1 |
| Chouinard, VA | 1 |
| Öngür, D | 1 |
| Li, C | 1 |
| Wang, A | 1 |
| Wang, C | 1 |
| Ramamurthy, J | 1 |
| Zhang, E | 1 |
| Guadagno, E | 1 |
| Trakadis, Y | 1 |
| Sun, F | 2 |
| Yu, C | 1 |
| Liu, X | 2 |
| Wang, D | 2 |
| Liu, N | 1 |
| Liu, J | 1 |
| Teng, L | 1 |
| Kerling, A | 1 |
| Tegtbur, U | 1 |
| Ziegenbein, M | 1 |
| Grams, L | 1 |
| Heinze, DR | 1 |
| Sieberer, M | 1 |
| Xin, C | 1 |
| Lihong, W | 1 |
| Qiuyuan, L | 1 |
| Hongzhuo, L | 1 |
| Qing, Y | 1 |
| Yang, J | 1 |
| Wan, C | 1 |
| Keller-Varady, K | 1 |
| Hasan, A | 1 |
| Schneider-Axmann, T | 1 |
| Hillmer-Vogel, U | 1 |
| Adomßent, B | 1 |
| Wobrock, T | 1 |
| Schmitt, A | 1 |
| Niklas, A | 1 |
| Falkai, P | 1 |
| Malchow, B | 1 |
| Elmorsy, E | 1 |
| Shahda, M | 1 |
| Mahmoud, el-HM | 1 |
| Rakha, SA | 1 |
| Shoaib, M | 1 |
| Zhao, J | 1 |
| Wang, L | 1 |
| Fan, C | 1 |
| Yu, K | 1 |
| Zhao, X | 1 |
| Liu, W | 1 |
| Su, Z | 1 |
| Dean, B | 1 |
| Thomas, N | 1 |
| Scarr, E | 1 |
| Udawela, M | 1 |
| Fujii, T | 1 |
| Hattori, K | 1 |
| Miyakawa, T | 1 |
| Ohashi, Y | 1 |
| Sato, H | 1 |
| Kunugi, H | 1 |
| Rowland, LM | 1 |
| Pradhan, S | 1 |
| Korenic, S | 1 |
| Wijtenburg, SA | 1 |
| Hong, LE | 1 |
| Edden, RA | 1 |
| Barker, PB | 1 |
| Nahata, T | 1 |
| Saini, TR | 1 |
| Regenold, WT | 1 |
| Phatak, P | 1 |
| Marano, CM | 1 |
| Sassan, A | 1 |
| Conley, RR | 1 |
| Kling, MA | 1 |
| Beasley, CL | 1 |
| Dwork, AJ | 1 |
| Rosoklija, G | 1 |
| Mann, JJ | 1 |
| Mancevski, B | 1 |
| Jakovski, Z | 1 |
| Davceva, N | 1 |
| Tait, AR | 1 |
| Straus, SK | 1 |
| Honer, WG | 1 |
| Su, ZX | 1 |
| Shi, YN | 1 |
| Teng, LS | 1 |
| Li, X | 1 |
| Wang, LX | 1 |
| Meng, QF | 1 |
| Teng, LR | 1 |
| Li, YX | 1 |
| Amann, LC | 1 |
| Gandal, MJ | 1 |
| Lin, R | 1 |
| Liang, Y | 2 |
| Siegel, SJ | 2 |
| Herberth, M | 1 |
| Koethe, D | 1 |
| Cheng, TM | 1 |
| Krzyszton, ND | 1 |
| Schoeffmann, S | 1 |
| Guest, PC | 1 |
| Rahmoune, H | 1 |
| Harris, LW | 1 |
| Kranaster, L | 1 |
| Leweke, FM | 1 |
| Bahn, S | 1 |
| das Neves Duarte, JM | 1 |
| Kulak, A | 1 |
| Gholam-Razaee, MM | 1 |
| Cuenod, M | 1 |
| Gruetter, R | 1 |
| Do, KQ | 1 |
| Vasic, N | 1 |
| Connemann, BJ | 1 |
| Wolf, RC | 1 |
| Tumani, H | 1 |
| Brettschneider, J | 1 |
| Uehara, T | 1 |
| Itoh, H | 1 |
| Matsuoka, T | 1 |
| Rujescu, D | 1 |
| Genius, J | 1 |
| Seo, T | 1 |
| Sumiyoshi, T | 1 |
| MITIS, ZK | 1 |
| HARRIS, T | 1 |
| NOWINSKI, WW | 1 |
| ALTSCHULE, MD | 1 |
| HENNEMAN, DH | 1 |
| HOLLIDAY, P | 1 |
| GONCZ, RM | 1 |
| EASTERDAY, OD | 1 |
| FEATHERSTONE, RM | 1 |
| GOTTLIEB, JS | 1 |
| NUSSER, ML | 1 |
| HOGG, RV | 1 |
| Rabin, C | 1 |
| Ehrlichman, RS | 1 |
| Budhian, A | 1 |
| Metzger, KL | 1 |
| Majewski-Tiedeken, C | 1 |
| Winey, KI | 1 |
| Halim, ND | 1 |
| Lipska, BK | 1 |
| Hyde, TM | 1 |
| Deep-Soboslay, A | 1 |
| Saylor, EM | 1 |
| Herman, MM | 1 |
| Thakar, J | 1 |
| Verma, A | 1 |
| Kleinman, JE | 1 |
| Lima, L | 1 |
| Carreira, I | 1 |
| Morales, M | 1 |
| Silva, C | 1 |
| Casique, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dietary Supplement N-acetylcysteine (NAC) as a Novel Complementary Medicine to Improve Cognitive Disfunction in Schizophrenia[NCT01885338] | Phase 1 | 26 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for lactic acid and Dementia Praecox
| Article | Year |
|---|---|
Brain lactate and pH in schizophrenia and bipolar disorder: a systematic review of findings from magnetic resonance studies.
Topics: Bipolar Disorder; Brain; Humans; Hydrogen-Ion Concentration; Lactic Acid; Schizophrenia | 2018 |
Metabolomics in patients with psychosis: A systematic review.
Topics: 3-Hydroxybutyric Acid; Aspartic Acid; Biomarkers; Bipolar Disorder; Creatine; Female; Glutamic Acid; | 2018 |
Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?
Topics: Biogenic Monoamines; Biomarkers; Blood-Brain Barrier; Cannabinoids; Cell Count; Cytokines; Databases | 2012 |
28 other studies available for lactic acid and Dementia Praecox
| Article | Year |
|---|---|
Development of intranasal implantable devices for schizophrenia treatment.
Topics: Drug Carriers; Humans; Lactic Acid; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; | 2022 |
Inhibition of glycolysis prevents behavioural changes in mice with MK801-induced SCZ model by alleviating lactate accumulation and lactylation.
Topics: Animals; Dizocilpine Maleate; Glycolysis; HMGB1 Protein; Lactic Acid; Mice; Schizophrenia | 2023 |
Long Acting Polycaprolactone Based Parenteral Formulation of Aripiprazole Targeting Behavioural and Biochemical Deficit in Schizophrenia.
Topics: Animals; Aripiprazole; Delayed-Action Preparations; Lactic Acid; Microscopy, Electron, Scanning; Mic | 2021 |
Juvenile social isolation leads to schizophrenia-like behaviors via excess lactate production by astrocytes.
Topics: Animals; Astrocytes; Glucose; Glycogen Phosphorylase; Lactic Acid; Male; Oxidative Phosphorylation; | 2021 |
Butyl stearate prolongs the drug release period of isoperidone‑loaded poly (lactic‑co‑glycolic acid) microspheres: In vitro and in vivo investigation.
Topics: Animals; Delayed-Action Preparations; Dogs; Drug Compounding; Drug Liberation; Humans; Lactic Acid; | 2019 |
Exercise capacity and quality of life in patients with schizophrenia.
Topics: Adolescent; Adult; Blood Pressure; Case-Control Studies; Exercise Test; Exercise Tolerance; Female; | 2013 |
Injectable long-term control-released in situ gels of hydrochloric thiothixene for the treatment of schizophrenia: preparation, in vitro and in vivo evaluation.
Topics: Animals; Antipsychotic Agents; Benzoates; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dr | 2014 |
Increased serum fibroblast growth factor 21 levels in patients with schizophrenia.
Topics: Adult; Case-Control Studies; Citric Acid Cycle; Female; Fibroblast Growth Factors; Humans; Ketogluta | 2015 |
Endurance training in patients with schizophrenia and healthy controls: differences and similarities.
Topics: Adult; Exercise; Exercise Therapy; Female; Heart Rate; Humans; Lactic Acid; Male; Middle Aged; Oxyge | 2016 |
Blood lactate levels as a biomarker of antipsychotic side effects in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Biomarkers; Bipolar Disorder; Case-Control Studies; Dyskinesia, Drug-In | 2016 |
Development of near zero-order release PLGA-based microspheres of a novel antipsychotic.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Chemistry, Pharmaceutical; Delayed-Action Prepa | 2017 |
Evidence for impaired glucose metabolism in the striatum, obtained postmortem, from some subjects with schizophrenia.
Topics: Acetyl Coenzyme A; Adult; Blood Glucose; Case-Control Studies; Corpus Striatum; Energy Metabolism; F | 2016 |
Metabolic profile alterations in the postmortem brains of patients with schizophrenia using capillary electrophoresis-mass spectrometry.
Topics: Adult; Analysis of Variance; Brain; Electrophoresis, Capillary; Female; Glycylglycine; Humans; Lacti | 2017 |
Elevated brain lactate in schizophrenia: a 7 T magnetic resonance spectroscopy study.
Topics: Adult; Brain; Case-Control Studies; Female; Gyrus Cinguli; Humans; Lactic Acid; Magnetic Resonance S | 2016 |
D-optimal designing and optimization of long acting microsphere-based injectable formulation of aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Cholesterol; Delayed-Action Preparations; Lactic Acid; Microsphe | 2008 |
Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis.
Topics: Adult; Biomarkers; Bipolar Disorder; Blood Glucose; Case-Control Studies; Female; Glucose; Humans; L | 2009 |
Metabolic abnormalities in fronto-striatal-thalamic white matter tracts in schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Anisotropy; Autopsy; Brain; Corpus Striatum; Diffusion Magn | 2009 |
Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.
Topics: Antipsychotic Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Lactic Acid; Microsphe | 2011 |
In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia.
Topics: Absorbable Implants; Animals; Antipsychotic Agents; Drug Delivery Systems; Humans; Lactic Acid; Male | 2010 |
Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Enterotoxins; Female; Glucose Transporter Type 1; Hexoki | 2011 |
N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development.
Topics: Acetylcysteine; Alanine; Animals; Aspartic Acid; Cerebral Cortex; Disease Models, Animal; Free Radic | 2012 |
Effect of transient blockade of N-methyl-D-aspartate receptors at neonatal stage on stress-induced lactate metabolism in the medial prefrontal cortex of adult rats: role of 5-HT1A receptor agonism.
Topics: Animals; Caudate Nucleus; Dizocilpine Maleate; Isoindoles; Lactic Acid; Male; Microdialysis; Models, | 2012 |
The levels of peripheral blood lactic acid in psychiatric patients treated by EST, with or without the use of a muscle paralysant.
Topics: Blood; Convulsive Therapy; Electroconvulsive Therapy; Humans; Lactic Acid; Mental Disorders; Psychot | 1954 |
Carbohydrate metabolism in brain disease. VI. Lactate metabolism after infusion of sodium d-lactate in manic-depressive and schizophrenic psychoses.
Topics: Bipolar Disorder; Brain Diseases; Carbohydrate Metabolism; Humans; Lactic Acid; Mental Disorders; Ps | 1956 |
Blood glutathione, lactic acid, and pyruvic acid relationships in schizophrenia.
Topics: Exercise; Glutathione; Humans; Lactic Acid; Pyruvic Acid; Schizophrenia | 1952 |
In vitro and in vivo demonstration of risperidone implants in mice.
Topics: Animals; Behavior, Animal; Biocompatible Materials; Disease Models, Animal; Drug Delivery Systems; D | 2008 |
Increased lactate levels and reduced pH in postmortem brains of schizophrenics: medication confounds.
Topics: Animals; Antipsychotic Agents; Artifacts; Brain; Brain Chemistry; Brain Diseases, Metabolic; Cerebel | 2008 |
[Treatment of patients with panic disorder and an elevated urinary excretion of MHPG using imipramine or clonazepam].
Topics: Adult; Anxiety Disorders; Clonazepam; Depression; Female; Humans; Imipramine; Lactates; Lactic Acid; | 1992 |